12:00 AM
 | 
May 07, 2012
 |  BC Week In Review  |  Company News  |  Deals

Amarantus BioSciences Inc., Rainbow Coral deal

Amarantus and Rainbow Coral's Rainbow BioSciences LLC executed a letter of intent to develop Amarantus' Parkinson's disease program that includes early detection diagnostic blood test NuroPro and mesencephalic astrocyte-derived neurotrophic factor (MANF), a protein that mediates apoptosis. The companies said the diagnostic...

Read the full 188 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >